Immunotherapies for postural orthostatic tachycardia syndrome, other common autonomic disorders and Long COVID: Current state and future direction

Svetlana Blitshteyn^*Gabriela Funez-dePagnierAnna SzombathyMeagan Hutchinson

• Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, United States

Postural orthostatic tachycardia syndrome (POTS), neurocardiogenic syncope, and orthostatic hypotension are the most common autonomic disorders encountered in clinical practice. Autoimmune etiology and association of these conditions with systemic autoimmune and inflammatory disorders, autonomic neuropathy and post-acute infectious syndromes, including Long COVID, suggest that immunotherapies should be considered as a therapeutic option, at least in a subset of patients. However, treatment of common autonomic disorders has traditionally included pharmacologic and non-pharmacologic symptomatic therapies as the standard approach. Unfortunately, these symptomatic therapies have been of limited or insufficient efficacy to meaningfully improve functional status or result in recovery, especially in patients with severe symptomatology. Case reports, case series, and clinical experience suggest that intravenous and subcutaneous immunoglobulin as well as other immunologic therapies, such as plasmapheresis, corticosteroids and rituximab, may be effective in some patients with severe POTS and other common autonomic disorders who are refractory to standard therapies. In this narrative review, we summarize the literature available on the topic of immunotherapies in POTS, other common autonomic disorders, and Long COVID. We also highlight the need for large, multi-center, placebo-controlled trials of immunoglobulin, plasmapheresis, intermittent corticosteroids and other repurposed immunotherapies in patients with common autonomic disorders who have significant functional impairment.